• Home
  • INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy.

INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy.

Author List
Ronald C. Chen, Theodore Karrison, Colleen Anne Lawton, William Adrian Hall, Hala Borno, Mihaela Rosu, Ashesh B. Jani, David M. Schuster, Michael J. Seider, Jason A. Efstathiou, Edwin Melencio Posadas, Paul L. Nguyen, Felix Y Feng
Publication
Journal of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/179825647
Publication Year
2021
Publication Title
Ronald C. Chen, Theodore Karrison, Colleen Anne Lawton, William Adrian Hall, Hala Borno, Mihaela Rosu, Ashesh B. Jani, David M. Schuster, Michael J. Seider, Jason A. Efstathiou, Edwin Melencio Posadas, Paul L. Nguyen, Felix Y Feng. INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):tps179-tps179.